https://charts.traderzeitung.de/phases/CA25253X2077 string(1415) "{"isin":"CA25253X2077","name":"DiaMedica Therapeutics Inc","stock_id_xnas":7927489,"stock_id_xnys":null,"generated_at":"2026-09-24 01:32:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":7.25,"close_at":"2026-09-21 21:55:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":7.79,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":7.4483},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":7.58,"close_at":"2026-09-23 21:58:00","complete":true,"perf_pct":-2.6958},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":7.58,"close_at":"2026-09-23 22:00:00","complete":false,"perf_pct":0}]}]}"

DiaMedica Therapeutics Aktie News & Nachrichten

[WKN: A2N9HB | Symbol: DMAC]

Realtimekurs

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über DiaMedica Therapeutics gefunden werden.

DiaMedica Therapeutics Nachrichtenticker öffnen

MT Newswires 23.06.2026 15:27 Uhr

DiaMedica Therapeutics verabreicht ersten Patienten Dosen in Phase-2-Studie zur fetalen Wachstumsrestriktion

09:26 AM EDT, 06/23/2026 (MT Newswires) -- DiaMedica Therapeutics (DMAC) teilte am Dienstag mit, dass es die ersten beiden Patienten in einer klinisch

MT Newswires 16.06.2026 15:06 Uhr

DiaMedica Therapeutics erhält US-FDA-Leitlinien zu den nichtklinischen Anforderungen für DM199

09:05 AM EDT, 06/16/2026 (MT Newswires) -- DiaMedica Therapeutics (DMAC) erhielt schriftliches Feedback von der US-amerikanischen Food and Drug Admini